Zobrazeno 1 - 10
of 610
pro vyhledávání: '"Jaw‐Ching Wu"'
Autor:
Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 3, Pp 406-420 (2024)
Background/Aims The performance of machine learning (ML) in predicting the outcomes of patients with hepatocellular carcinoma (HCC) remains uncertain. We aimed to develop risk scores using conventional methods and ML to categorize early-stage HCC pat
Externí odkaz:
https://doaj.org/article/0f7a40cce036484188ab058ab3f60d00
Autor:
Chia-Chu Fu, Cheng-Yi Wei, Chi-Jen Chu, Pei-Chang Lee, Teh-Ia Huo, Yi-Hsiang Huang, Yee Chao, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
Publikováno v:
Journal of the Formosan Medical Association, Vol 122, Iss 7, Pp 593-602 (2023)
Background: Alpha fetoprotein (AFP) is the most widely used tumor marker for hepatocellular carcinoma (HCC). Nevertheless, few studies have investigated the prognostic factors of HCC patients with normal serum AFP levels. Methods: We retrospectively
Externí odkaz:
https://doaj.org/article/edf8869eec864fc383441d4d0df6257b
Autor:
Chun-Yang Lee, Gar-Yang Chau, Cheng-Yi Wei, Yee Chao, Yi-Hsiang Huang, Teh-Ia Huo, Ming-Chih Hou, Yu-Hui Su, Jaw-Ching Wu, Chien-Wei Su
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract We investigated the outcomes of patients with ruptured hepatocellular carcinoma (HCC) and identified the optimal treatment modality for such patients. We retrospectively enrolled 91 patients with treatment-naive HCC and tumor rupture at diag
Externí odkaz:
https://doaj.org/article/e831e7417d424e70aebcc8468c272c0e
Autor:
Hsien‐Hong Lin, Shih‐Jer Hsu, Sheng‐Nan Lu, Wan‐Long Chuang, Chao‐Wei Hsu, Rong‐Nan Chien, Sien‐Sing Yang, Wei‐Wen Su, Jaw‐Ching Wu, Tzong‐Hsi Lee, Cheng‐Yuan Peng, Kuan‐Chiao Tseng, Albert Qin, Yi‐Wen Huang, Pei‐Jer Chen
Publikováno v:
JGH Open, Vol 5, Iss 8, Pp 929-940 (2021)
ABSTRACT Background and Aim Ropeginterferon alfa‐2b (P1101) is a novel long‐acting mono‐PEGylated recombinant proline interferon (IFN) conjugated to a 40 kDa branched polyethylene glycol (PEG) chain at its N‐terminus, allowing every‐two‐w
Externí odkaz:
https://doaj.org/article/d99d520d83e548769c19cb86c1436144
Autor:
Yuh-Jin Liang, Cheng-Pu Sun, Yu-Chen Hsu, Yi-Wen Chen, I-An Wang, Chien-Wei Su, Mi-Hua Tao, Jaw-Ching Wu
Publikováno v:
Journal of Biomedical Science, Vol 27, Iss 1, Pp 1-17 (2020)
Abstract Background Hepatitis D virus (HDV) infection may induce fulminant hepatitis in chronic hepatitis B patients (CHB) or rapid progression of CHB to cirrhosis or hepatocellular carcinoma. There is no effective treatment for HDV infection. HDV en
Externí odkaz:
https://doaj.org/article/4858e7056bd14fbb8d5fe236ceb4409e
Autor:
Chien-Wei Su, Kuan-Chieh Fang, Rheun-Chuan Lee, Chien-An Liu, Ping-Hsien Chen, Pei-Chang Lee, Wei-Yu Kao, Yi-Hsiang Huang, Teh-Ia Huo, Ming-Chih Hou, Han-Chieh Lin, Jaw-Ching Wu
Publikováno v:
Journal of the Formosan Medical Association, Vol 119, Iss 2, Pp 610-620 (2020)
Background/Purpose: Whether esophagogastric varices (EGV) can determine the outcome of patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) remains unknown. This study aimed to assess the impact of EGV on the prog
Externí odkaz:
https://doaj.org/article/7c7ad8f30de04fe7b2fc9fba1d3713f1
Autor:
Po-Chun Chen, Wei-Yu Kao, Yuan-Lung Cheng, Yuan-Jen Wang, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
Publikováno v:
Journal of the Formosan Medical Association, Vol 119, Iss 1, Pp 42-50 (2020)
Background/purpose: The impact of non-alcoholic fatty liver disease (NAFLD) on the prevalence of chronic kidney disease (CKD) is not fully elucidated. We aimed to assess the correlation between NAFLD and CKD in a large population study. Methods: We i
Externí odkaz:
https://doaj.org/article/0fd212aacf5e4402aed99d1355725995
Autor:
Chih‐Li Chen, Yu‐Shuen Tsai, Yen‐Hua Huang, Yuh‐Jin Liang, Ya‐Yun Sun, Chien‐Wei Su, Gar‐Yang Chau, Yi‐Chen Yeh, Yung‐Sheng Chang, Jui‐Ting Hu, Jaw‐Ching Wu
Publikováno v:
Hepatology Communications, Vol 2, Iss 11, Pp 1392-1407 (2018)
Lymphoid enhancer factor 1 (LEF1) activity is associated with progression of several types of cancers. The role of LEF1 in progression of hepatocellular carcinoma (HCC) remains poorly known. We investigated LEF1 expression in HCC and its interactions
Externí odkaz:
https://doaj.org/article/0005d62db0a740039803f2ea121212ef
Autor:
Wei‐Yu Kao, Elise Chia‐Hui Tan, Hsin‐Lun Lee, Yi‐Hsiang Huang, Teh‐Ia Huo, Chun‐Chao Chang, Jeng‐Fong Chiou, Ming‐Chih Hou, Jaw‐Ching Wu, Chien‐Wei Su
Publikováno v:
Alimentary Pharmacology & Therapeutics. 57:1299-1312
Publikováno v:
Cells, Vol 11, Iss 4, p 634 (2022)
Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encount
Externí odkaz:
https://doaj.org/article/c21c6e4c0af9434ba980e10ac9c518b4